ATE428778T1 - Verfahren zum screening auf agonistische antikörper - Google Patents
Verfahren zum screening auf agonistische antikörperInfo
- Publication number
- ATE428778T1 ATE428778T1 AT03719213T AT03719213T ATE428778T1 AT E428778 T1 ATE428778 T1 AT E428778T1 AT 03719213 T AT03719213 T AT 03719213T AT 03719213 T AT03719213 T AT 03719213T AT E428778 T1 ATE428778 T1 AT E428778T1
- Authority
- AT
- Austria
- Prior art keywords
- agonistic antibodies
- screening
- dependent
- antibodies
- effective screening
- Prior art date
Links
- 230000001270 agonistic effect Effects 0.000 title abstract 3
- 238000012216 screening Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 230000003305 autocrine Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002127260 | 2002-04-26 | ||
| PCT/JP2003/005372 WO2003091424A1 (fr) | 2002-04-26 | 2003-04-25 | Procede de criblage d'un anticorps agoniste |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE428778T1 true ATE428778T1 (de) | 2009-05-15 |
Family
ID=29267644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03719213T ATE428778T1 (de) | 2002-04-26 | 2003-04-25 | Verfahren zum screening auf agonistische antikörper |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7732149B2 (de) |
| EP (1) | EP1505148B1 (de) |
| JP (1) | JP4518941B2 (de) |
| AT (1) | ATE428778T1 (de) |
| AU (1) | AU2003235833A1 (de) |
| DE (1) | DE60327199D1 (de) |
| WO (1) | WO2003091424A1 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0015055A (pt) * | 1999-10-20 | 2002-07-16 | Genentech Inc | Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr |
| US7393532B1 (en) * | 2000-10-18 | 2008-07-01 | Genentech, Inc. | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003042405A2 (en) * | 2001-11-15 | 2003-05-22 | Children's Medical Center Corporation | Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof |
| ATE428778T1 (de) | 2002-04-26 | 2009-05-15 | Chugai Pharmaceutical Co Ltd | Verfahren zum screening auf agonistische antikörper |
| WO2005035753A1 (ja) | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| WO2005035754A1 (ja) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| WO2006043615A1 (ja) * | 2004-10-21 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | 免疫抑制受容体の用途 |
| EP1828250A2 (de) * | 2004-12-16 | 2007-09-05 | Genentech, Inc. | Methoden zur behandlung von autoimmunkrankheiten |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| EP2824183B1 (de) * | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur Herstellung bispezifischer Antikörper |
| ES2460517T3 (es) | 2005-07-25 | 2014-05-13 | Emergent Product Development Seattle, Llc | Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20 |
| WO2007114325A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 二重特異性抗体を精製するための抗体改変方法 |
| IN2014DN10515A (de) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
| EP2418223A3 (de) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Einkettige, multivalente Bindungsproteine mit Effektorfunktion |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| JP6013915B2 (ja) | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| HRP20192255T1 (hr) | 2011-08-05 | 2020-03-06 | Regeneron Pharmaceuticals, Inc. | Humanizirani miševi s univerzalnim lakim lancem |
| CA2872908C (en) | 2012-05-10 | 2023-11-14 | Gerhard Frey | Multi-specific monoclonal antibodies |
| SG10201803449VA (en) | 2013-09-27 | 2018-05-30 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
| SG10201808225TA (en) | 2014-03-21 | 2018-10-30 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
| TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定ｆｖｉｉｉ的反應性之方法 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| HK1250038A1 (zh) | 2015-03-19 | 2018-11-23 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| MX2018003292A (es) | 2015-09-21 | 2018-08-01 | Aptevo Res & Development Llc | Polipéptidos de unión a cd3. |
| JP6954842B2 (ja) | 2015-12-25 | 2021-10-27 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| CA3004288C (en) | 2015-12-28 | 2025-05-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION |
| AU2017255077B2 (en) | 2016-04-28 | 2024-05-16 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| AU2017303205B2 (en) | 2016-07-29 | 2024-08-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity |
| IL265144B2 (en) | 2016-09-06 | 2024-10-01 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| US20210139601A1 (en) * | 2017-05-25 | 2021-05-13 | The Broad Institute, Inc. | Lymphocyte antigen cd5-like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer agonists and methods of use thereof |
| TW202423960A (zh) | 2017-09-29 | 2024-06-16 | 日商中外製藥股份有限公司 | 具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑 |
| BR112020008393A2 (pt) | 2017-11-01 | 2020-11-03 | Chugai Seiyaku Kabushiki Kaisha | variante e isoforma de anticorpos com atividade biológica reduzida |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| US20210024631A1 (en) * | 2018-03-28 | 2021-01-28 | Orionis Biosciences, Inc. | Bi-functional proteins and construction thereof |
| KR20210009421A (ko) | 2018-06-14 | 2021-01-26 | 바이오아트라, 엘엘씨 | 다중 특이적 항체 구조체 |
| US20220233638A1 (en) | 2019-03-28 | 2022-07-28 | Waseda University | Cell competition inhibitor |
| WO2025159531A1 (ko) * | 2024-01-23 | 2025-07-31 | 재단법인대구경북과학기술원 | 수용체 이량체화를 유도하는 작용제 항체를 스크리닝 하는 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| JP2928287B2 (ja) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DK0584348T3 (da) | 1992-03-11 | 2005-09-19 | Powderject Vaccines Inc | Genetisk vaccine mod immundefektvirusser |
| DK0979281T3 (da) | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| AU750453B2 (en) | 1997-10-03 | 2002-07-18 | Chugai Seiyaku Kabushiki Kaisha | Natural human antibody |
| AU2333999A (en) | 1998-01-23 | 1999-08-09 | Prolifaron, Inc. | Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors |
| GB2344886B (en) | 1999-03-10 | 2000-11-01 | Medical Res Council | Selection of intracellular immunoglobulins |
| WO2001079494A1 (fr) | 2000-04-17 | 2001-10-25 | Chugai Seiyaku Kabushiki Kaisha | Anticorps agonistes |
| WO2002033072A1 (fr) | 2000-10-20 | 2002-04-25 | Chugai Seiyaku Kabushiki Kaisha | Anticorps degrade, agoniste de tpo |
| ATE428778T1 (de) | 2002-04-26 | 2009-05-15 | Chugai Pharmaceutical Co Ltd | Verfahren zum screening auf agonistische antikörper |
-
2003
- 2003-04-25 AT AT03719213T patent/ATE428778T1/de not_active IP Right Cessation
- 2003-04-25 DE DE60327199T patent/DE60327199D1/de not_active Expired - Lifetime
- 2003-04-25 JP JP2004501976A patent/JP4518941B2/ja not_active Expired - Lifetime
- 2003-04-25 EP EP03719213A patent/EP1505148B1/de not_active Expired - Lifetime
- 2003-04-25 US US10/511,993 patent/US7732149B2/en not_active Expired - Lifetime
- 2003-04-25 AU AU2003235833A patent/AU2003235833A1/en not_active Abandoned
- 2003-04-25 WO PCT/JP2003/005372 patent/WO2003091424A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2003091424A1 (ja) | 2005-09-02 |
| EP1505148B1 (de) | 2009-04-15 |
| DE60327199D1 (de) | 2009-05-28 |
| EP1505148A4 (de) | 2006-07-26 |
| JP4518941B2 (ja) | 2010-08-04 |
| US20050164307A1 (en) | 2005-07-28 |
| WO2003091424A1 (fr) | 2003-11-06 |
| US7732149B2 (en) | 2010-06-08 |
| EP1505148A1 (de) | 2005-02-09 |
| AU2003235833A1 (en) | 2003-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE428778T1 (de) | Verfahren zum screening auf agonistische antikörper | |
| EP2283831A3 (de) | Biomarker zur Vorauswahl von Patienten für die Anti-IGF1R-Therapie | |
| DE60308093D1 (de) | Zellkultivierungsvorrichtung und diese benutzende Verfahren zur Zellsortierung | |
| ATE440864T1 (de) | Verwendung von il-23-antagonisten; verwandte reagenzien | |
| NO20052181D0 (no) | Fremgangsmate og apparat for a posisjonere et sentrum for en seismisk kilde | |
| ATE510439T1 (de) | Verfahren und vorrichtung zum bestimmen, übermitteln und/oder verwenden von verzögerungsinformationen | |
| EP3889252A4 (de) | Mikroträger für zellkultur, verfahren zu seiner herstellung und zellkulturverfahren damit | |
| DE60327315D1 (de) | Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind | |
| DE60321356D1 (de) | Verfahren zur diagnostik von eierstock endometriose | |
| DE50310037D1 (de) | Träger zum tragen von zumindest einem anzeigeapparat | |
| TW200626900A (en) | Wnt proteins and detection and treatment of cancer | |
| TW200626899A (en) | Frizzled proteins and detection and treatment of cancer | |
| ATE544783T1 (de) | Neutralisierende anti tlr4/md-2 antikörper und verfahren zu deren verwendung | |
| DE602005007728D1 (de) | Modulare Anordnung und Verfahren zum Züchten von Wassertieren | |
| NO20053344L (no) | Fremgangsmate for a generere en genetisk modifisert organisme for a screene aktive substanser. | |
| ATE513215T1 (de) | Monoklonale antikörper, hybridomzellinien, verfahren und kits zum nachweis von phytase | |
| ATE502155T1 (de) | Verfahren zum reaktiv-färben von leder, sowie farbstoffe und deren verwendung | |
| EP3995310A4 (de) | Gehäuseanordnung und herstellungsverfahren dafür sowie elektronische vorrichtung | |
| DE50310109D1 (de) | Verfahren zum einfärben von düngemitteln | |
| DE502004007244D1 (de) | Verfahren zum spezifischen schnellnachweis getr nkesch dlicher mikroorganismen | |
| WO2020154548A3 (en) | Antibodies specific to delta 1 chain of t cell receptor | |
| EP4134425A4 (de) | Mikroträger für zellkultur, verfahren zur herstellung davon und zellkulturzusammensetzung damit | |
| ATE390692T1 (de) | Verfahren zum trennen und reinigen von cäsium-131 von bariumnitrat | |
| DE60306895D1 (de) | Verfahren zum übermitteln von Datenströmen über optischen Verbindungen, System und Computerprogramprodukte | |
| WO2007098393A3 (en) | Compounds and methods for treating diseases with trpv4 channel receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |